Moloxin (Moxifloxacin)

Moxifloxacin, the active ingredient in Moloxin, is a fluoroquinolone presented as an injection for intravenous use. It treats a broad spectrum of bacterial infections in adults and children when prescribed by a qualified healthcare professional.

GNH USA supplies Moloxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable products. Clients benefit from consistent batch release, regulatory support, and on‑time delivery across EU and global markets.

Moxifloxacin is indicated for several serious bacterial infections affecting the respiratory, skin, intra‑abdominal and ocular systems. - Community‑acquired pneumonia: effective eradication of susceptible pathogens in adult and pediatric patients. - Acute bacterial sinusitis: rapid symptom relief and bacterial clearance. - Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load and improves lung function. - Skin and soft tissue infections: treats cellulitis, abscesses and other infections caused by susceptible organisms. - Intra‑abdominal infections: provides coverage for mixed aerobic and anaerobic bacteria in complicated cases. - Bacterial conjunctivitis: resolves ocular infection caused by susceptible strains.

Moxifloxacin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Injection site pain - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Tendon rupture or tendinopathy - QT interval prolongation and arrhythmias - Severe allergic reactions including anaphylaxis - Clostridioides difficile‑associated diarrhea - Hepatic failure or severe liver injury - Stevens‑Johnson syndrome and toxic epidermal necrolysis

When using Moloxin, clinicians should consider several precautionary measures to minimize risk. - Renal impairment: assess renal function and adjust therapy as needed. - Hepatic impairment: monitor liver enzymes and use with caution. - QT prolongation risk: avoid in patients with known arrhythmias or concurrent QT‑prolonging drugs. - Pregnancy category C: prescribe only when the potential benefit justifies the potential fetal risk. - Concomitant fluoroquinolone use: avoid co‑administration to prevent additive toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin. - Warfarin: may increase INR and bleeding risk. - Theophylline: can raise theophylline plasma concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal effectiveness; consider alternative contraception. - Diabetic agents: potential for hypoglycaemia; monitor blood glucose levels.